Market Overview

Benzinga's Top Initiations

Related THLD
Threshold Pharmaceuticals Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma
Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented At The 2014 ASH Annual Meeting
Related ANV
Allied Nevada Gold Spikes On Rumor It Seeks Investment Partner
5 Smart Money Managers Taking A Shine To Gold Miners

Analysts at William Blair initiated coverage on shares of Threshold Pharmaceuticals (NASDAQ: THLD) with an “outperform” rating. Threshold Pharmaceuticals' shares closed at $8.15 yesterday. Threshold Pharmaceuticals had $49.73 million in total cash for the latest quarter.

Scotia Capital initiated coverage on shares of Allied Nevada Gold (AMEX: ANV) with an “outperform” rating. Allied Nevada Gold's stock closed at $28.08 yesterday. Allied Nevada Gold's trailing-twelve-month operating margin is 35.98%.

JMP Securities initiated coverage on shares of Darling International (NYSE: DAR) with a “market perform” rating. Darling's shares closed at $16.18 yesterday. Darling's trailing-twelve-month revenue is $1.74 billion.

Analysts at Roth Capital initiated coverage on shares of Harmonic (NASDAQ: HLIT) with a “neutral” rating. Harmonic's shares closed at $4.21 yesterday. Harmonic's PEG ratio is 1.41.

Latest Ratings for THLD

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy
Sep 2014HC WainwrightInitiates Coverage onBuy
Feb 2013Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for THLD
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ANV + DAR)

Around the Web, We're Loving...

Get Benzinga's Newsletters